冷循环射频消融术治疗原发性肝癌患者疗效及外周血Treg细胞的变化观察

doi:10.3969/j.issn.1672-5069.2021.01.032

Abstract

Abstract: Objective The aim of this study was to investigate the short-term efficacy of radiofrequency ablation (RFA) with cold circulation in the treatment of patients with primary liver cancer (PLC) and the change of peripheral blood fegulatory T cells (Treg). Methods A total of 94 patients with PLC were admitted to our hospital between April 2018 and April 2019, and were randomly divided into observation group (n=47) and control group (n=47). The patients in the control group received hepatic artery chemoembolization (TACE), while those in the observation group received RFA with cold circulation under the guidance of color ultrasound. The percentages of peripheral blood Treg cells were detected by TCM. Results At the end of three month after operation, the complete response, partial response and disease stable rates in the RFA-treated patients were 42.6%,40.4% and 6.4%, and the disease control rate was 89.4%, all significantly higher than (31.9%, 27.7%, 12.8%, and 72.3%, P＜0.05】 in TACE-treated patients except for disease stable rate; at presentation, serum ALT, ALP, total bilirubin and the percentage of peripheral blood cells in RFA-treated patients were (96.4±22.4)U/L, (184.5±30.5)U/L,(18.5±5.8)μmol/L and 9.5±1.5)%, not significantly different compared to in TACE-treated patients, while serum ALT, ALP and percentage of peripheral blood Treg cells in RFA-treated patients were (35.1±5.8)U/L,(84.5±15.8)U/L and (6.2±0.5)% after operation, all significantly lower than in TACE-treated patients; the incidence of post operation complications such as abdominal distension, diarrhea, peritonitis, fever and gastrointestinal bleeding was 8.5%, significantly lower than 25.5% (P＜0.05)in TACE-treated group.Conclusion The application of RFA with cold circulation under color ultrasound guidance in treatment of patients with PLC could get excellent short-term efficacy, which might reduce peripheral blood Treg cells, and has a higher safety.

Key words: Hepatoma, Cold recycling, Radiofrequency ablation, Peripheral blood Treg cells, Therapy

Li Yamin, Wang Ruiting, Wang Yingying. Short-term efficacy of radiofrequency ablation with cold circulation in the treatment of patients with primary liver cancer[J]. Journal of Practical Hepatology, 2021, 24(1): 123-126.

References

[1] Kudo M. Breakthroughs in the management of hepatocellular carcinoma: celebrating 50 years of the liver cancer study group of Japan. Oncology, 2014, 87(1):1-6.
[2] Malki A, El-Sharkawy A, EL-Sayed M, et al. Antitumor activities of the novel isosteviol derivative 10c against liver cancer. Anticancer Res, 2017, 37(4):1591-1601.
[3] Petrick JL, Braunlin M, Laversanne M, et al. International trends in liver cancer incidence, overall and by histologic subtype, 1978-2007. Int J Cancer, 2016, 139(7):1534-1545.
[4] Valery PC, Laversanne M, Clark PJ, et al. Projections of primary liver cancer to 2030 in 30 countries worldwide. Hepatology, 2018, 67(2):600-611.
[5] Nakashima T, Okuda K, Kojiro M, et al. Primary liver cancer coincident with schistosomiasis Japonica. a study of 24 necropsies. Cancer, 1975, 36(4):1483-1489.
[6] Zhao H, Liu F, Yue Z, et al. Association of hepatic vein lipiodol tram-track sign during transcatheter arterial chemoembolization with perioperative death. J Int Medical Res, 2017, 45(3):1148-1157.
[7] Carr BI, Kondragunta V, Buch SC, et al. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer, 2010, 116(5):1305-1314.
[8] 中华人民共和国卫生部. 原发性肝癌诊疗规范(2011年版). 中华肝脏病杂志, 2012, 20(6):929-946.
[9] Riaz A, Memon K, Miller FH, et al. Role of EASL, RECIST and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol, 2011, 54(4):695.
[10] 李靖, 朱文良, 康鑫鑫, 等. 经肝动脉化疗栓塞联合射频消融治疗原发性肝癌的预后影响因素及预测模型. 中华肿瘤杂志, 2017, 39(10):787-791.
[11] 王秀清, 马艳君, 詹晋莉. 肝动脉化疗栓塞术联合超声引导下微波消融术治疗特殊部位原发性肝癌患者疗效及安全性分析. 实用肝脏病杂志, 2019, 22(2):260-263.
[12] Kim YS, Rhim H, Tae K, et al. Radiofrequency ablation of benign cold thyroid nodules: initial clinical experience. Thyroid, 2006, 16(4):361-367.
[13] Weusten BL, Bergman JJ. Cryoablation for managing Barret’s esophagus refractory to radiofrequency ablation? Don’t embrace the cold too soon! Gastrointest Endosc, 2015, 82(3):449-451.
[14] Liapi E, Geschwind JF. Chemoembolization for primary and metastatic liver cancer. Cancer J, 2010, 16(2):156-162.
[15] Imai N, Katano Y, Kuzuya T, et al. An increase in lesion density can predict lower local recurrence after transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatogastroenterology, 2013, 60(125):965-970.
[16] Tait IS, Yong SM, Cuschieri SA. Laparoscopic in situ ablation of liver cancer with cryotherapy and radiofrequency ablation. Br J Surg, 2002, 89(12):1613-1619.
[17] 张宝芳, 程明亮, 陆爽, 等. 替诺福韦及替比夫定对贵州地区不同基因型HBeAg阳性乙肝孕妇HBV RNA的影响. 中华医学杂志, 2018, 98(43):3503.
[18] Hira K, Tariq RM, Sultana V, et al. Effect of seaweeds occurring at Karachi coast on mosquito larvae and liver function in rats. Pak J Pharm Sci, 2017, 30(2):387-391.
[19] 罗葆明, 杨焰, 智慧, 等. 射频消融术中二维声像图强回声区大小与消融范围的相关性研究. 中华超声影像学杂志, 2008, 17(2):130-132.
[20] Garrean S, Hering J, Saied A, et al. Radiofrequency ablation of primary and metastatic liver tumors: a critical review of the literature. Am J Surg, 2008, 195(4):516-520.

Short-term efficacy of radiofrequency ablation with cold circulation in the treatment of patients with primary liver cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Li Xiaoyan, Hu Heping. Internal management of patients with primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(1): 1-3.
[2]	Zhou Xinmin, Ding Xiaopeng. Highlights of conventional supporting therapy for patients with primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(1): 4-6.
[3]	Liu Qi, Hao Jiqing. Immunotherapy of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2021, 24(1): 7-9.
[4]	Zheng Zhiheng, Li Weiyun, Hui Zhenyu,et al. Serological and virological response topegylated interferon α-2a and entecavir combination in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2021, 24(1): 19-22.
[5]	Lin Jinxiang, Yang Keli. Comparison of response toPEG-IFNα-2a or PEG-IFNα-2b in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2021, 24(1): 27-30.
[6]	Fan Bingdong, Zhang Guohua, Wang Jun. An observation of clinical efficacy of sofosbuvir/vipatavir and ribavirin combination in the treatment of patients with chronic hepatitis C [J]. Journal of Practical Hepatology, 2021, 24(1): 31-34.
[7]	Yang Xiaodong,Jia Ting,Zhang Xiuling, et al. Short-term efficacy of danorevir and peginterferon-α in the treatment of patients with genotype 3 infected chronic hepatitis C [J]. Journal of Practical Hepatology, 2021, 24(1): 35-38.
[8]	Wei Xiuqin, Yan Xiaoxia, Shi Guorong, et al. Short-termefficacy of atorvastatin and tiopronin combination in the treatment of patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2021, 24(1): 47-50.
[9]	Li Zhao, Huang Zansong , Li Fan. Application of fenofibrate and bicyclol combination in treatment of patients with non-alcoholic fatty liver diseases and changes of hepatic PPARγ₂ [J]. Journal of Practical Hepatology, 2021, 24(1): 59-62.
[10]	Chen Jinyu, Guo Xiaoxia, Zhong Xiaoni. Efficacy of bifidobacterium triple viable capsuleand metformin in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2021, 24(1): 63-66.
[11]	Chen Yanping, Huang Shaoqiang,Deng Xin ,et al. Short-term efficacy of tiopronin and polyene phosphatidylcholine combination in treatment of patients with alcoholic liver disease [J]. Journal of Practical Hepatology, 2021, 24(1): 67-70.
[12]	Cai Yu, Wang Mengchun, Qiu Xinping, et al. Improvement of liver function and subsiding jaundice by compound glycyrrhizin and adenosylmethionine succinate in the treatment of patients with alcoholic hepatitis [J]. Journal of Practical Hepatology, 2021, 24(1): 71-74.
[13]	Wu Chang,Tian Yuan,Liu Hongyan. Short-term efficacy of live clostridium butyricum in assisting tiopronin and metadoxine in treatment of patients with alcoholic liver disease [J]. Journal of Practical Hepatology, 2021, 24(1): 75-78.
[14]	Li Qingling, He Shuguang, Yi Xiaoming, et al. Changes of peripheral blood lymphocyte PD-1 and PD-L1 expression in patients with autoimmune hepatitis receiving tripterygium wilfordii polyglycosides and magnesium iso-glycyrrhizate [J]. Journal of Practical Hepatology, 2021, 24(1): 79-82.
[15]	Zeng Jiao, Guo Guihai. Efficacy and safety of polyethylene glycol and lactulose in the treatment of patients with hepatic encephalopathy:a Meta-analysis [J]. Journal of Practical Hepatology, 2021, 24(1): 99-102.